Hear it First from our team of Data Science Experts
Why should you attend?
CBI’s 5th Annual Clinical Data Disclosure and Transparency conference will help to navigate regulatory changes at both the U.S. and international level. Develop strategies..
d-Wise appoints VP of d-Wise Europe and establishes German office in response to rapid international growth
- Demand for d-Wise’s clinical trials de-identification solutions soars following new regulatory demands in Europe
- The strategic choice of Frankfurt puts d-Wise in the centre of a major pharmaceutical..
As the life sciences industry prepares for compliance with EMA Policy 0070 and its requirements for the anonymization of shared clinical study reports, d-Wise has been previewing its powerful Blur..
The latest version of the software, Blur CSR (due for release in December), offers enhanced risk management plus new controls for medical writers producing clinical study reports. (d-Wise booth at..
For the past decade, there has been more and more of a push toward clinical data standardization, and with the Prescription Drug User Fee Act (PDUFA) authorizing the FDA to mandate clinical trial..
Eli Lilly Takes the Lead
As pharma companies move beyond the “blockbuster” model of drug development, the industry is bursting with new ideas and ways to think about the future. The innovation..
Search technology is designed to create efficiencies to save both time and money. In the world of clinical trials, search technology specifically designed for the clinical trial workflow offers even..
In March of this year, an Emerging Technology working group was formed at the FDA/PhUSE Annual Computational Science Symposium. The group was launched with two main areas of focus: metadata..